Quebec City, October 3, 2017
Panthera Dental announced today itspartnership with TVM Life Science Ventures VII and Emerillon Capital venture capitals in order to support its export activities.
With this financial assistance, Panthera Dental will be able to pursue its international expansion and continue to be a leader in its field. Ever since its creation, Panthera Dental has been growing with accelerating speed thanks to its innovating products in the fields of dental implantology and sleep disordered breathing. Panthera Dental is now proud to be associated with two partners of excellent reputation, in addition to Capital Croissance PME, in order to promote its commercial expansion and offer its custom products to a larger number of people.
“I am proud to partner with world-class venture capital funds to ensure that Panthera Dental will become a major player in its field. Those investments enable us to consolidate our physical establishment in the United States and in Europe while also allowing us to keep up with the rapid growth of our export, which we have been experiencing now for several years.” – Gabriel Robichaud, CEO, Panthera Dental.
“Panthera Dental commercialises innovative products targeting wide-ranging international markets. Our investment will position Panthera Dental as a world leader and concurrently keep its corporate roots in the province of Quebec. Panthera Dental will benefit from TVM Life Science Ventures VII’s European and North- American network to facilitate its market access abroad.” – Dr. Luc Marengere, Senior Partner, TVM Life Science Ventures VII.
“We are enthusiastically partnering with Gabriel Robichaud and his team at Panthera Dental, a manufacturer recognized for the excellence of its products. Our investment will enable the company to accelerate its growth, mainly abroad, by drawing in part on the network of CIC Capital, Emerillon Capital’s lead sponsor.” – Pierre Cantin, Senior Investment Director, CIC Capital, on behalf of Emerillon Capital.
Panthera Dental will establish a subsidiary in the United States as well as in Europe and will increase its production capabilities in the months to come to better meet demand in those regions. Given the company’s success and the loyalty demonstrated by its current customers, emphasis will be placed on the training of all health professionals of the field in order to better promote its unrivaled quality products.